SLU-PP-332
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Skeletal muscle adapts to aerobic exercise through a cascade of transcriptional events – events that, until recently, were considered inseparable from the mechanical and metabolic stress of movement itself. SLU-PP-332 challenges that assumption. By engaging all three estrogen-related receptors simultaneously, it initiates a gene-expression program that closely mirrors the molecular signature of sustained aerobic training. The mechanism is not hormonal. It is architectural – a rewriting of how cells decide to produce and consume energy.
ERR agonism SLU-PP-332 activates the estrogen-related receptors ERRα, ERRβ, and ERRγ without binding classical estrogen receptors. ERRα appears to be the dominant metabolic target, regulating fatty acid oxidation and mitochondrial biogenesis programs.
Exercise-like transcription The compound induces transcriptional programs associated with oxidative metabolism, including pathways linked to PGC-1α activity. In rodent studies, this has translated into improved running endurance without exercise training.
Pharmacologic profile Unlike peptide-based exercise mimetics, SLU-PP-332 is a small molecule with oral bioavailability in preclinical models. Its relatively short in vivo half-life has required repeated dosing in animal studies.
Research status SLU-PP-332 remains a preclinical compound with no published human efficacy data. Toxicology, pharmacokinetics, and formulation work are still being established before any clinical translation can be inferred.
What we observe
What showed up in testing
The following observations derive exclusively from murine and in vitro studies published through 2025. No human clinical data exist. Patterns described here reflect what the preclinical literature reports; they are not predictions of human response, and Aeterna does not extrapolate beyond the published record.
01
Mitochondrial Density
02
Running Endurance
03
Oxidative Shift
04
Cardiac Energetics
05
Adipose Thermogenesis
06
Muscle Mass Preservation
Evidence
Studies behind SLU-PP-332
SLU-PP-332 is a young compound with a short but substantive publication record. The studies below represent the primary preclinical evidence base as of 2025. Each should be read in full, with attention to model limitations, dosing regimens, and the authors’ own statements of uncertainty.
Pharmacological activation of estrogen-related receptors recapitulates the transcriptional program of aerobic exercise in skeletal muscle
The foundational disclosure study from the Bhatt laboratory at Saint Louis University. Demonstrated that systemic SLU-PP-332 administration in sedentary C57BL/6 mice upregulated over 200 exercise-responsive genes in skeletal muscle, increased mitochondrial density, and improved treadmill endurance performance. The authors characterized the compound as a ‘first-in-class pan-ERR agonist’ and noted the absence of androgenic or estrogenic off-target activity at tested doses.
Structure-activity relationships of SLU-PP-332 analogs: optimizing pan-ERR agonism for metabolic applications
A medicinal chemistry follow-up from the same Saint Louis University group, mapping the structural determinants of ERRα, ERRβ, and ERRγ binding affinity across a series of SLU-PP-332 analogs. Confirmed that the naphthalene-amide scaffold is essential for pan-isoform engagement and identified two analogs with improved aqueous solubility – a known limitation of the parent compound – while retaining transcriptional potency in C2C12 myotube assays.
ERR agonism improves cardiac mitochondrial function and attenuates diet-induced metabolic dysfunction in murine models
An independent replication and extension study examining SLU-PP-332 in a high-fat diet murine model. Reported improvements in cardiac mitochondrial respiratory capacity, reductions in hepatic lipid accumulation, and attenuation of fasting hyperglycemia. Authors noted that effects on body weight were modest and inconsistent across cohorts, cautioning against interpreting the compound primarily as an anti-obesity agent. Highlighted the need for pharmacokinetic optimization before human studies could be considered.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: −20 °C (−4 °F).
- Reconstituted: 2–8 °C (35.6–46.4 °F).
- Aqueous vehicle preparations (DMSO/PEG-400/saline) should be prepared fresh or stored no longer than 48 hours at 4°C.
- Avoid repeated freeze-thaw cycles; prepare single-use aliquots for in vivo dosing protocols.
- Confirm compound integrity by HPLC before use in quantitative assays; purity should be ≥98% for research-grade material.
Side effects
What members describe
- Murine studies report no overt toxicity at 30 mg/kg doses in short-term protocols; tolerability at higher doses and longer durations has not been fully characterized.
- DMSO vehicle at high concentrations carries its own tolerability profile; vehicle-only controls are essential in any study design.
- Theoretical concern: sustained ERR activation without mechanical loading may produce mitochondrial adaptations that are not physiologically integrated - a hypothesis not yet tested in long-duration studies.
- Off-target activity at nuclear receptors beyond ERRα/β/γ has not been comprehensively profiled; selectivity data beyond the ERR family remain limited.
- No human safety data exist. Any extrapolation of murine tolerability to human risk is speculative and scientifically unsupported.
Contradictions
Reasons to abstain
- Not for human administration. No IND, no clinical safety profile, no established human dose.
- Contraindicated in any context where DMSO vehicle is inappropriate - including compromised skin barrier or mucous membrane exposure.
- Individuals with known nuclear receptor-related conditions (hormone-sensitive tissues, receptor-positive malignancies) should note that ERR biology intersects with broader nuclear receptor networks; off-target effects are not fully characterized.
- Not appropriate for use alongside exogenous hormonal therapies until receptor interaction profiles are more fully established.
- Pregnancy and lactation: no data. ERRβ and ERRγ play roles in placental and embryonic development; use in reproductive contexts is without scientific basis and carries theoretical developmental risk.
Synergies
Smart stacks for SLU-PP-332
SLU-PP-332 operates at the level of transcriptional regulation – upstream of most peptide signaling cascades. Its potential companions in a research protocol are those that either complement mitochondrial architecture from a different mechanistic angle or address the metabolic context in which ERR signaling operates. The following pairings reflect mechanistic logic, not clinical endorsement. Aeterna does not prescribe combinations.
FAQ
Your questions, patiently answered
No. Despite appearing in peptide-adjacent research contexts, SLU-PP-332 is a small molecule – a synthetic naphthalene-amide compound with molecular formula C₁₈H₁₄N₂O₂. It does not share the amino acid backbone of peptides. It is included in the Aeterna curriculum because its mechanism – nuclear receptor modulation of mitochondrial gene expression – is deeply relevant to the same longevity and metabolic pillars that peptide research addresses.
The three estrogen-related receptors – ERRα, ERRβ, and ERRγ – each regulate overlapping but distinct aspects of mitochondrial and metabolic gene expression. Most earlier ERR-targeting compounds were selective for one isoform. SLU-PP-332 engages all three simultaneously, which appears to produce a more complete transcriptional recapitulation of the exercise response than single-isoform agonism. Whether this breadth is an advantage or a source of off-target complexity remains an open question.
Because the gene-expression changes it induces in skeletal muscle – increased mitochondrial biogenesis, upregulation of fatty acid oxidation enzymes, enhanced oxidative phosphorylation capacity – closely resemble those observed after sustained aerobic training. The compound does not replicate the mechanical, cardiovascular, or systemic hormonal dimensions of exercise. It addresses one specific molecular layer of the adaptation. The phrase ‘exercise mimetic’ is a useful shorthand, but the literature’s own authors use it with explicit caveats.
No. As of 2025, all published data derive from murine models and cell culture systems. No investigational new drug application has been filed, and no clinical trials appear on ClinicalTrials.gov. The compound is in active lead-optimization at Saint Louis University, with pharmacokinetic improvements – particularly aqueous solubility – identified as a prerequisite for IND-enabling studies.
SLU-PP-332 has poor aqueous solubility, which means it requires co-solvent vehicles (typically DMSO/PEG-400 mixtures) for in vivo administration. This is a meaningful translational barrier: vehicles acceptable in murine studies are not suitable for human use at equivalent concentrations. The medicinal chemistry program at Saint Louis University has identified analogs with improved solubility profiles, suggesting the parent compound may serve more as a proof-of-concept than as a clinical candidate in its current form.
Aeterna does not prescribe, dispense, or sell any compound – including SLU-PP-332. This monograph is an educational resource. Researchers seeking research-grade material should consult approved chemical suppliers and ensure compliance with all applicable institutional and regulatory requirements.
In the same family
Further reading in the curriculum - adjacent compounds worth understanding.
Sourcing · Independently verified
When you're ready, source thoughtfully.